People · Operator
Named in public records as an officer, director or promoter · active 2008–2014 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| AtheroNova Inc. | — | Pharmaceuticals | Series A | $18.9M | $15.5M | 2010 |
| AtheroNova Operations, Inc. | — | Biotechnology | Series A | $5.5M | $180.8M | 2008 |
Mark Selawski at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Selawski on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Thomas Gardner | 1 | 6 |
| Johan M Spoor | 1 | 3 |
| Thomas W. Gardner | 1 | 1 |
| Alexander W. Polinsky | 1 | 1 |
| Chaim W. Davis | 1 | 1 |
| Fred W. Knoll | 1 | 1 |
| Gary W. Freeman | 1 | 1 |
| Alexander W. Polinksy | 1 | 1 |
| Filiberto W. Zadini | 1 | 1 |
| Boris Ratiner | 1 | 1 |
| Filiberto Zadini | 1 | 1 |
| Giorgio Zadini | 1 | 1 |
| Boris W. Ratiner | 1 | 1 |
| Aaron Sandoval | 1 | 1 |
| Paul W. DiPerna | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.